Literature DB >> 29408337

Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant.

Bashar M Bata1, Jose S Pulido1, Sanjay V Patel1, Shakila P Khan2, Diva Salomao3, Thomas G Boyce4, Erick D Bothun5.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) has rarely been associated with ocular manifestations. We report a case of bilateral ocular involvement by PTLD with histopathologic features of extranodal marginal zone (MALT) lymphoma in an 8-year-old boy following orthotopic heart transplantation. The anterior segment disease was treated successfully using a combination of intraocular and systemic injections of humanized anti-CD20 antibody (rituximab).
Copyright © 2018 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29408337     DOI： 10.1016/j.jaapos.2017.10.016

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


  3 in total

1.  Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder.

Authors:  Pallavi Galera; Richard Flavin; Natasha M Savage; Annapurna Saksena; Shunyou Gong; Huan-You Wang; Niall Swan; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2020-10       Impact factor: 6.298

2.  Ultra-low-dose (boom-boom) radiotherapy for management of recurrent ocular post-transplant lymphoproliferative disorder.

Authors:  Konstantin V Astafurov; Erick D Bothun; Nadia N Laack; Amanda J Deisher; Sanjay V Patel; Lauren A Dalvin
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-15

Review 3.  Primary central nervous system lymphoma after heart transplantation: A case report and literature review.

Authors:  Fang Zhu; Qiuhui Li; Tao Liu; Yin Xiao; Huaxiong Pan; Xinxiu Liu; Gang Wu; Liling Zhang
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.